Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tianjin Pharmaceutical Da Ren Tang GroupSTU:2TZ -0.82%71 ROC (Joel Greenblatt) % is 76.64% as of Mar. 2026, which is 133% above its 10-year median of 32.92. GuruFocus rates STU:2TZ with a GF Score™ of 71/100 and a GF Value™ of €1.64 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 982 Drug Manufacturers companies, Tianjin Pharmaceutical Da Ren Tang Group ranks better than 93.38% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Tianjin Pharmaceutical Da Ren Tang Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 76.64%.
STU:2TZ'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 24.47 Med: 32.92 Max: 134.31
Current: 98.84
During the past 13 years, Tianjin Pharmaceutical Da Ren Tang Group's highest ROC (Joel Greenblatt) % was 134.31%. The lowest was 24.47%. And the median was 32.92%.
STU:2TZ's ROC (Joel Greenblatt) % is ranked better than 93.38% of 982
companies
in the Drug Manufacturers industry
Industry Median: 11.405
vs STU:2TZ: 98.84
Tianjin Pharmaceutical Da Ren Tang Group (STU:2TZ) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tianjin Pharmaceutical Da Ren Tang Group ROC (Joel Greenblatt) % Chart
Tianjin Pharmaceutical Da Ren Tang Group Annual Data
STU:2TZ vs ZTS: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Tianjin Pharmaceutical Da Ren Tang Group's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tianjin Pharmaceutical Da Ren Tang Group ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Tianjin Pharmaceutical Da Ren Tang Group's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Tianjin Pharmaceutical Da Ren Tang Group's ROC (Joel Greenblatt) % falls into.
Tianjin Pharmaceutical Da Ren Tang Group ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 76.64% mean?
Tianjin Pharmaceutical Da Ren Tang Group (STU:2TZ) has a ROC (Joel Greenblatt) % of 76.64% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Tianjin Pharmaceutical Da Ren Tang Group and its competitors. This is 133% above median its historical median of 32.92. Over the past decade, Tianjin Pharmaceutical Da Ren Tang Group's ROC (Joel Greenblatt) % has ranged from 24.47 to 134.31. According to the industry distribution chart, Tianjin Pharmaceutical Da Ren Tang Group ranks #65 out of 982 companies in the Drug Manufacturers industry, placing it in the top 6.6%.
Is Tianjin Pharmaceutical Da Ren Tang Group's ROC (Joel Greenblatt) % too high?
Tianjin Pharmaceutical Da Ren Tang Group's current ROC (Joel Greenblatt) % of 76.64% is 133% above median its 10-year median of 32.92. Over the past 10 years, this metric has ranged from a low of 24.47 to a high of 134.31. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 11.41. Tianjin Pharmaceutical Da Ren Tang Group's value of 76.64% is 572% above this industry median. Based on the distribution chart, Tianjin Pharmaceutical Da Ren Tang Group ranks #65 out of 982 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Tianjin Pharmaceutical Da Ren Tang Group has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tianjin Pharmaceutical Da Ren Tang Group's ROC (Joel Greenblatt) % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Tianjin Pharmaceutical Da Ren Tang Group ranks #65 out of 982 companies for ROC (Joel Greenblatt) %. This places Tianjin Pharmaceutical Da Ren Tang Group in the top 7% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 11.41. Tianjin Pharmaceutical Da Ren Tang Group's value of 76.64% is 572% above this benchmark. Historically, Tianjin Pharmaceutical Da Ren Tang Group's own ROC (Joel Greenblatt) % has ranged from 24.47 to 134.31 over the past decade. While the company's 10-year median is 32.92 vs. the industry median of 11.41, Tianjin Pharmaceutical Da Ren Tang Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.41, based on 982 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tianjin Pharmaceutical Da Ren Tang Group's current ROC (Joel Greenblatt) % of 76.64% is 572% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Tianjin Pharmaceutical Da Ren Tang Group and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tianjin Pharmaceutical Da Ren Tang Group's current ROC (Joel Greenblatt) % is 76.64%, which is 133% above median its own 10-year median of 32.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tianjin Pharmaceutical Da Ren Tang Group stock overvalued right now?
Based on GuruFocus' analysis, Tianjin Pharmaceutical Da Ren Tang Group (STU:2TZ) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.64, compared to a current price of €2.42 — trading 47.6% above its estimated fair value. The current ROC (Joel Greenblatt) % is 76.64%, which is 133% above median its 10-year median of 32.92 and 572% above the Drug Manufacturers industry median of 11.41. Tianjin Pharmaceutical Da Ren Tang Group's overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Tianjin Pharmaceutical Da Ren Tang Group (STU:2TZ), the current ROC (Joel Greenblatt) % is 76.64% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tianjin Pharmaceutical Da Ren Tang Group (STU:2TZ) Overvalued in 2026?
Based on GuruFocus' analysis, Tianjin Pharmaceutical Da Ren Tang Group stock appears to be overvalued.
The current stock price of €2.42 is trading 47.6% above its estimated GF Value™ of €1.64.
GuruFocus considers Tianjin Pharmaceutical Da Ren Tang Group to be Significantly Overvalued.
Key valuation signals for STU:2TZ:
ROC (Joel Greenblatt) %: 76.64% (133% above median its 10-year median of 32.92)
GF Value™: €1.64 vs. price of €2.42 (47.6% above fair value)
Industry Position: 572% above the Drug Manufacturers median (#65 of 982)
No single metric tells the full story. See the STU:2TZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tianjin Pharmaceutical Da Ren Tang Group Business Description
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd is a pharmaceutical manufacturing company. The company is engaged in the production and sale of traditional Chinese medicine, Western medicine, healthcare products, and investment holding. It operates in two segments, namely the Chinese Medicine segment and the Western Medicine segment. The Chinese Medicine segment manufactures Chinese pharmaceutical products under brands owned by the group. The Western Medicine segment manufactures Western pharmaceutical products through cooperation with foreign companies. The company earns the majority of its revenue from the sale of Chinese medicine.
71GF Score
Get the complete analysis for STU:2TZ
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2TZ has been successfully added to your 
